Skip to main content
. 2022 Oct 26;128(1):21–29. doi: 10.1038/s41416-022-01991-4

Fig. 1. Trial schema.

Fig. 1

mCRPC metastatic castration-resistant prostate cancer, ARSI androgen-receptor signalling inhibitor, ICI immune-checkpoint inhibitor, ECOG PS Eastern Cooperative Oncology Group Performance status, RECIST Response Evaluation Criteria in Solid Tumours, AUC area under the curve, G3-4 Grade 3 or 4, PSA prostate-specific antigen, PFS progression-free survival, PCWG Prostate Cancer Working Group.